RianJasonDicksteinMDF.A.C.S.

Urology • Hanover, MD

Surgical Oncology

Clinical Assistant Professor, Surgery, University of Maryland School of Medicine

Join to view full profile

Dr. Dickstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dickstein's full profile

Already have an account?

Office
7580 Buckingham Blvd
Suite 110
Hanover, MD 21076
Phone+1 410-760-9400

Fax+1 410-787-1911

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Urologic Surgical Oncology, 2010 - 2012
Boston University Medical CenterResidency, Urology, 2006 - 2010
Boston University Medical CenterInternship, Transitional Year, 2005 - 2006
Rutgers Robert Wood Johnson Medical SchoolClass of 2005

Certifications & Licensure

MD State Medical License 2012 - 2026
TX State Medical License 2010 - 2014
American Board of Urology Urology

Publications & Presentations

PubMed

1 citations
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua
Nature Medicine. 2024-08-01
1 citations
Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.
Yair Lotan, Piyush Agarwal, Peter Black, Rian Dickstein, Ashish M Kamat
Urologic Oncology. 2024-08-01
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua
Nature Medicine. 2024-08-01

Press Mentions

UMMS in the NewsApril 15th, 2021
Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ PatientsMay 21st, 2018